GSK and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully finalize negotiations for JEMPERLI plus chemotherapy for all adult patients with primary advanced or first recurrent endometrial cancer
- This milestone is a key step toward public reimbursement; decisions now rest with provincial and territorial governments to ensure patients can benefit from this important treatment.
MISSISSAUGA, ONTARIO – GSK is pleased to announce it has successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for Jemperli (dostarlimab for injection) in combination with carboplatin and paclitaxel for the treatment of adult patients with primary advanced or first recurrent endometrial cancer who are candidates for systemic therapy, including patients with mismatch repair proficient (MMRp)/microsatellite stable (MSS) tumours, representing approximately 75% of patients diagnosed with endometrial cancer. The negotiation concluded on December 2, 2025 with a letter of intent (LOI).
“The successful negotiation between GSK and the pCPA is a critical step forward in improving access to innovative treatment options for patients facing advanced or recurrent endometrial cancer,” said Tania Vrionis, CEO of Ovarian Cancer Canada. “With endometrial cancer being the most common gynecologic cancer and its prevalence steadily increasing in Canada over the past two decades, this announcement underscores the importance of ensuring access to therapies that have the potential to significantly impact patient outcomes and quality of life. We applaud GSK’s commitment to addressing the needs of the broader patient community and their dedication to advancing care in gynaecologic oncology.”
GSK remains committed to ensuring timely public access to Jemperli for people living with endometrial cancer. Through close collaboration with the pCPA via its Targeted Negotiation Process (TNP), part of the pCPA’s expedited negotiation pathways, GSK has successfully concluded negotiations for the expanded indication of Jemperli. The pCPA’s leadership and shared commitment to partnering to deliver and ensure patient access to innovative therapies is welcomed by GSK, especially as cancer — including women’s cancers — continues to rise in Canada.
“We’re pleased to see a successful negotiation for Jemperli for adult patients with primary advanced or first recurrent endometrial cancer, through our TNP,” said Mauro Chies, Chief Executive Officer, pCPA. “This is a great example of an expedited negotiation process in action, with partners collaborating to reach an agreement, which supports the timely coverage of new drugs for patients who need them.”
This milestone underscores the need to expedite public reimbursement and, as such, GSK looks forward to working with provincial and territorial governments and other key stakeholders to ensure Jemperli is accessible through public drug plans for the broader population of patients with primary advanced or recurrent endometrial cancer.
“Public reimbursement is critical to ensuring eligible endometrial cancer patients have access to this important treatment option,” said Sridhar Venkatesh, President & General Manager, GSK Canada.“This milestone represents meaningful progress, and we look forward to engaging in productive discussions with regional governments and stakeholders.”
About endometrial cancer
Endometrial cancer is found in the inner lining of the uterus, known as the endometrium. Endometrial cancer is the most common gynaecologic cancer in developed countries ii, with an estimated 1.6 million people living with active disease at any stage and 417,000 new cases reported each year worldwide.iii Incidence rates are expected to rise by approximately 40% between 2020 and 2040.iv In Canada, an estimated 8,600 women were diagnosed with endometrial cancer in 2024, with approximately 1,600 succumbing to the disease.v Approximately 15-20% of patients with endometrial cancer will be diagnosed with advanced disease at the time of diagnosis.vi Among patients with primary advanced or recurrent endometrial cancer, approximately 75% have MMRp/MSS tumours.i
About Jemperli (dostarlimab for injection)
Jemperli is a programmed death receptor-1 (PD-1)-blocking antibody that binds to the PD-1 receptor and blocks its interaction with the PD-1 ligands PD-L1 and PD-L2.vii In Canada, Jemperli (dostarlimab for injection) is indicated in combination with carboplatin and paclitaxel for the treatment of adult patients with primary advanced or first recurrent endometrial cancer who are candidates for systemic therapy which includes patients with MMRp/MSS and dMMR/MSI-H tumours. Jemperli is also approved as monotherapy for the treatment of adult patients with dMMR/MSI-H recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing regimen.
Please consult the Product Monograph at www.gsk.ca for complete safety information. The Product Monograph is also available by calling 1-800-387-7374.
GSK in gynaecologic oncology
GSK is committed to maximizing patient survival through transformational medicines with a current effort on breakthroughs in oncology, including gynaecologic cancers, some of the most common cancers affecting women. We are focused on developing new medicines across a range of different modalities for a variety of cancers, including ovarian and endometrial.
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.ca.
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the “Risk Factors” section in GSK’s Annual Report on Form 20-F for 2024, and GSK’s Q2 Results for 2025.
References
i. Based on CMP:CancerMPact® [Patient Metrics], Cerner Enviza. Available from www.cancermpact.com.
ii. Faizan U, Muppidi V. Uterine Cancer. [Updated 2022 Sep 5]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan. Available at: www.ncbi.nlm.nih.gov/books/NBK562313/.
iii. Sung H, Ferlay J, Siegel R, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660.
iv. International Research on Cancer. Global Cancer Observatory. Cancer Tomorrow. Gco.iarc.fr/tomorrow/en/dataviz/.
v. Lee, S. (2021). Uterine cancer statistics. Canadian Cancer Society. https://cancer.ca/en/cancer-information/cancer-types/uterine/statistics.
vi. CMP: CancerMPact® Patient Metrics Mar-2023, Cerner Enviza. Available at www.cancermpact.com. Accessed 18 March 2025.
vii. Laken H, Kehry M, Mcneeley P, et al. Identification and characterization of TSR-042, a novel anti-human PD-1 therapeutic antibody. European Journal of Cancer. 2016;69,S102. doi:10.1016/s0959-8049(16)32902.